Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer

Abstract

Background: To assess the efficacy and safety of combination of PD-1 inhibitors, recombinant human endostatin (Rh-endostatin) and chemotherapy as first-line treatment for advanced non-small-cell lung cancer (NSCLC). Methods: A total of 100 patients with advanced NSCLC were retrospectively reviewed and analyzed (58 in the group receiving PD-1 inhibitors plus Rh-endostatin and chemotherapy; 42 in the group receiving Rh-endostatin and chemotherapy). The primary end point was progression-free survival. Results: Patients in the group receiving PD-1 inhibitors plus Rh-endostatin and chemotherapy had significantly improved progression-free survival (10.2 vs 6.5 months; p < 0.001) and objective response rate (67.2 vs 42.9%; p = 0.015), with acceptable toxicity. Conclusion: Our study showed the superiority of combination therapy of PD-1 inhibitors and Rh-endostatin as first-line treatment for advanced NSCLC.

Efficacy and safety of PD-1 inhibitors plus chemotherapy with or without endostatin for stage IV lung squamous cancer: a retrospective study

“…Notably, one case study reported that the addition of endostatin to PD-1 inhibitors and chemotherapy yielded significant results in treating stage IV LUSC ( 18 ). Furthermore, the combination has been attributed with promising efficacy and acceptable safety in the primary treatment of advanced NSCLC ( 10 , 19 ). Consequently, our retrospective analysis scrutinized the efficacy and safety of PD-1 inhibition with chemotherapy, both with and without the addition of endostatin, in stage IV LUSC treatment.…”

“…Endostatin (recombinant human vascular endostatin), targeting the endothelial cells of tumor vasculature, inhibits neovascularization, thereby impeding nutrient supply to tumor cells and curbing their proliferation and metastasis ( 9 ). As an anti-angiogenic agent, endostatin influences the tumor immune microenvironment similarly to PD-1 inhibitors, providing a rationale for their concurrent use ( 9 , 10 ). A retrospective clinical study has demonstrated that the combination of ICIs with endostatin offers greater efficacy and safety than the combination of ICIs with chemotherapy in treating advanced non-small cell lung cancer (NSCLC) ( 11 ).…”

Impact of Anti-angiogenic Drugs on Severity of COVID-19 in Patients with Non-Small Cell Lung Cancer

“… 27 In addition, several studies have shown the favorable efficacy of anti-angiogenic drugs in the treatment of advanced NSCLC. 26 , 28 – 33 To date, however, very few studies have confirmed the effect of anti-angiogenic drugs on the severity of COVID-19 in patients with NSCLC. To address this gap, we conducted this study to investigate the impact of anti-angiogenic drugs on COVID-19 severity in patients with NSCLC.…”